New York-presbyterian/queens - Medicare Acute Care Hospital in Flushing, NY

Name	New York-presbyterian/queens
Type	Acute Care Hospital
Location	56-45 Main Street, Flushing, New York
Ownership	Voluntary non-profit - Private
Emergency Services	Yes
Medicare ID (CCN)	330055

Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital

Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean

Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night

Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well

Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well

Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted

Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them

Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home

Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital

Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with New York-presbyterian/queens from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number	1023131174
Organization Name	NEW YORK HISPITAL QUEENS
Address	5645 Main St, Dept Obgyn, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1063535102
Organization Name	NEW YORK HOSPITAL QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	518-284-8237

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1063546547
Organization Name	NEW YORK HOSPITAL QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital - Critical Access
Phone Number	718-670-2007

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1073636585
Organization Name	NEW YORK HOSPITAL OF QUEENS
Address	5645 Main St, Flushing, NY 11533
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1093926347
Organization Name	NEW YORK HOSPITAL QUEENS
Address	5645 Main St, Wa 100, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-2627

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1114040268
Organization Name	NYHQ
Address	5645 Main St, Obgyn, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1124281712
Organization Name	DENNISON WE
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	516-670-2636

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1164954632
Organization Name	NEW YORK PRESBYTERIAN QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1231

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1396868436
Organization Name	NEW YORK HOSPITAL QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1538282686
Organization Name	NYHQ
Address	5645 Main St, Obgyn, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1619360831
Organization Name	NEW YORK HOSPITAL MEDICAL CENTER OF QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1572

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1649705633
Organization Name	NEW YORK PRESBYTERIAN-QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1231

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1659807162
Organization Name	NEW YORK PRESBYTERIAN QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	201-675-5609

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1669908273
Organization Name	NEW YORK PRESBYTERIAN-QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1231

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1689090995
Organization Name	NEW YORK HOSPITAL OF QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-2250

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1689100281
Organization Name	NYP QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-2000

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1689797722
Organization Name	NEW YORK HOSPITAL QUEENS
Address	5645 Main St, Obgyn Dept, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1699917120
Organization Name	NEW YORK HOSPITAL OF QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	Chronic Disease Hospital
Phone Number	718-661-7140

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1710009709
Organization Name	NEW YORK HOSPITAL QUEENS
Address	56-45 Main Street, Obgyn Dept., Flushing, NY 11335
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1770606816
Organization Name	NEW YORK HOSPITAL OF QUEENS
Address	5645 Main St, Obgyn, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1821152620
Organization Name	NEW YORK HOSPITAL OF QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1231

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1831212984
Organization Name	NYHQ
Address	5645 Main St, Obgyn, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1841313996
Organization Name	NEW YORK HOSPITAL QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1922121078
Organization Name	NEW YORK HOSPITAL OF QUEENS
Address	5645 Main St, Obgyn, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1952347205
Organization Name	NEWYORK-PRESBYTERIAN-QUEENS
Address	56-45 Main Street, Flushing, New York, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	518-284-8237

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1952766016
Organization Name	NEWYORK PRESBYTERIAN QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1575

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

NPI Number	1972626018
Organization Name	NEW YORK HOSPITAL OF QUEENS
Address	5645 Main St, Flushing, NY 11355
Hospital Type	General Acute Care Hospital
Phone Number	718-670-1517

News Archive

Endoscopic sleeve gastroplasty found to be safe and effective way for treating obese patients

A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure, and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

New model could help internet addicts realize problem and reduce usage

Research has shown that internet addicts do not always feel guilty about their usage, and in many cases, they do not even perceive their usage as problematic.

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Read more Medical News

› Verified 4 days ago

Able to receive lab results electronically	Yes
Able to track patients' lab results, tests, and referrals electronically between visits	Yes

Hospitals in Flushing, NY

New York-presbyterian/queens Acute Care Hospital Location: 56-45 Main Street, Flushing, New York 11355 Phone: (718) 670-2000
Flushing Hospital Medical Center Acute Care Hospital Location: 45th Avenue And Parsons Boulevard, Flushing, New York 11355 Phone: (718) 670-5000

Medicare Hospital Compare

Hospital Compare provide information about the quality of care at over 4,000 Medicare-certified hospitals across the country. You can use Hospital Compare to find hospitals and compare the quality of their care. The information on Hospital Compare:

• Helps you make decisions about where you get your health care
• Encourages hospitals to improve the quality of care they provide

In an emergency, you should go to the nearest hospital. When you can plan ahead, discuss the information you find here with your health care provider to decide which hospital will best meet your health care needs. Hospital Compare was created through the efforts of the Centers for Medicare & Medicaid Services (CMS), in collaboration with organizations representing consumers, hospitals, doctors, employers, accrediting organizations, and other federal agencies.